- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Adoptive immunotherapy.
Displaying page 1 of 1.
EudraCT Number: 2012-001335-31 | Sponsor Protocol Number: virus-specific_CD8_T-cells_001 | Start Date*: 2013-11-08 |
Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta | ||
Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation | ||
Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005594-21 | Sponsor Protocol Number: ADP-04511 | Start Date*: 2016-08-18 | |||||||||||
Sponsor Name:Adaptimmune LLC | |||||||||||||
Full Title: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma | |||||||||||||
Medical condition: Unresectable, metastatic or recurrent synovial sarcomas | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004240-30 | Sponsor Protocol Number: AIT-MULTIVIR-01 | Start Date*: 2014-06-18 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-sp... | |||||||||||||
Medical condition: Immune deficiency after allogeneic stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006146-34 | Sponsor Protocol Number: 100505 | Start Date*: 2008-04-30 |
Sponsor Name:Stage Pharmaceuticals GmbH | ||
Full Title: Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial | ||
Medical condition: -chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001929-27 | Sponsor Protocol Number: NK4AML | Start Date*: 2020-05-20 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study’ | ||
Medical condition: AML patients who do not have rapid progressive disease with or without disease controlling medication and who are not eligible for allogeneic SCT. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-007612-29 | Sponsor Protocol Number: UCL/09/0050 | Start Date*: 2013-02-26 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia | |||||||||||||
Medical condition: The medical condition under investigation is childhood precursor B acute lymphoblastic leukaemia (ALL). | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002130-30 | Sponsor Protocol Number: NSCLC-TKD/IL-2 | Start Date*: 2013-11-15 | |||||||||||
Sponsor Name:Technische Universität München Fakultät für Medizin | |||||||||||||
Full Title: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT) | |||||||||||||
Medical condition: Interventional phase II clinical trial incorporating a parallel control group of patients receiving no adjuvant immunotherapy. Patients with non small lung cell carcinoma (NSCLC) in stage III A and... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002311-26 | Sponsor Protocol Number: INMUNOCELL | Start Date*: 2021-12-09 | |||||||||||||||||||||||||||||||
Sponsor Name:IDIVAL | |||||||||||||||||||||||||||||||||
Full Title: PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN haploidentical PROGENITORS HEMATOPOIETIC TRANSPLANTATIONWITH ADOPTIVE CELL IMMUNOTHERAPY. | |||||||||||||||||||||||||||||||||
Medical condition: Primary prophylaxis of CMV infection in haploidentical transplantation of hematopoietic progenitors. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000872-14 | Sponsor Protocol Number: UCL/11/0519 | Start Date*: 2013-07-23 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant (ICAT) | ||||||||||||||||||
Medical condition: acute myeloid or acute lymphoblastic leukaemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003421-28 | Sponsor Protocol Number: TUD-HINKL1-059 | Start Date*: 2014-07-10 | |||||||||||
Sponsor Name:Technische Universität Dreden | |||||||||||||
Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia | |||||||||||||
Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003181-32 | Sponsor Protocol Number: CIMNK1001 | Start Date*: 2011-10-14 | ||||||||||||||||
Sponsor Name:Karolinska University Hospital | ||||||||||||||||||
Full Title: In vivo expansion and efficacy of adoptive natural killer cell-based immunotherapy for high-risk myeloid diseases | ||||||||||||||||||
Medical condition: acute myeloid leukemia and myelodysplastic syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006649-18 | Sponsor Protocol Number: 08/0214 | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy with CMV TCR-transduced Donor-derived T cells for Recipients of Allogeneic Haematopoietic Stem Cell ... | |||||||||||||
Medical condition: CMV reactivation/infection in post allogeneic haematopoietic stem cell transplant recipients. Allo-HSCT being performed for underlying haematological malignancy (eg, AML, ALL, NHL, Hodgkin Lymphoma... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002257-11 | Sponsor Protocol Number: C.A.S.T. | Start Date*: 2020-12-14 | |||||||||||
Sponsor Name:AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO | |||||||||||||
Full Title: A phase I study of adoptive immunotherapy with Cytokine-Induced Killer (CIK) cells in relapsed and non-resectable sarcomas after multimodal treatment. | |||||||||||||
Medical condition: patients with advanced and non-resectable sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002848-32 | Sponsor Protocol Number: M-2017-322 | Start Date*: 2018-05-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Miltenyi Biomedicine GmbH | |||||||||||||||||||||||||||||||||
Full Title: A phase I/II safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies. | |||||||||||||||||||||||||||||||||
Medical condition: Pediatric and adult patients with relapsed/refractory (r/r) CD19-expressing B cell acute lymphoblastic leukemia (ALL) and Non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL). | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
